Vimab Group AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
For the full year, sales was SEK 227.29 million compared to SEK 205.68 million a year ago. Revenue was SEK 229.25 million compared to SEK 209.04 million a year ago. Net loss was SEK 34.22 million compared to SEK 24.09 million a year ago. Basic loss per share from continuing operations was SEK 3.4 compared to SEK 8.9 a year ago.